02785nas a2200241   4500008004100000020001400041024001700055245009300072210006900165260027500234300001300509490000700522520185800529100001302387700001502400700001402415700001502429700001302444700001402457700001302471700001402484856004502498       2015                        eng d  a1365-3148  abu7, 930118200aRed cell alloimmunisation in regularly transfused beta thalassemia patients in Pakistan.0 aRed cell alloimmunisation in regularly transfused beta thalassem  aEnglandbZaidi,U. Department of Blood Transfusion, National Institute of Blood Disease and Bone Marrow Transplantation (NIBD), Karachi, Pakistan.Borhany,M. Department of Blood Transfusion, National Institute of Blood Disease and Bone Marrow Transplantation (NIBD),c2015  a106 - 100 v253 aBACKGROUND: In Pakistan routine blood group typing of thalassemia patients identifies ABO and Rh(D) antigens only. Therefore, other antigen incompatibilities between blood donor and blood recipient may cause alloimmunisation., OBJECTIVE: The aim of this study was to estimate the frequency of alloimmunisation and to evaluate the risk factors associated with its development in beta (beta)-thalassemia patients receiving regular blood transfusions., MATERIALS AND METHODS: In total 162 beta thalassemia patients were included in this study. An extended red cell antigen panel was performed to detect antibodies. Patients received red cell concentrates, which were matched for ABO and Rh(D) antigens. Clinical and laboratory data were collected and analysed to estimate the frequency of alloantibodies and the factors influencing immunisation in patients on regular blood transfusion., RESULTS: The median age of patients was 67 (range: 05-25) years. A total of 14 (86%) patients developed alloantibodies against red cell antigens. The most frequently occurring alloantibodies was anti-E (25%), anti-K (18%), anti-e (12%) and anti-D (06%). Five (31%) patients developed more than one red blood cell (RBC) alloantibody. Age at first transfusion in alloimmunised patients was 122+/-087years. The frequency of blood transfusion in alloimmunised patients was 23+/-881days and in those without alloimmunisation was 318+/-16days (p=002). Logistic regression analysis showed no independent risk factor associated with alloimmunisation., CONCLUSION: The frequency of transfusion was increased in patients who developed alloantibodies. Typing patients and donors to match for Rh and Kell antigens would prevent more than 90% of RBC alloantibodies and reduce the frequency of transfusion in thalassemia patients.Copyright © 2015 British Blood Transfusion Society.1 aZaidi, U1 aBorhany, M1 aAnsari, S1 aParveen, S1 aBoota, S1 aShamim, I1 aZahid, D1 aShamsi, T  uhttps://notifylibrary.org/reference/4404